ATE361318T1 - Polypeptiden, die die april-vermittelte aktivierung von t-und b-zellen hemmen - Google Patents

Polypeptiden, die die april-vermittelte aktivierung von t-und b-zellen hemmen

Info

Publication number: ATE361318T1
Authority: AT; Austria
Prior art keywords: april; taci; bcma; cell; agp
Prior art date: 2000-05-12

Application number

AT01935466T

Other languages

English (en)

Inventor

Lars Eyde Theill

Gang Yu

Original Assignee

Amgen Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-05-12

Filing date

2001-05-14

Publication date

2007-05-15

2001-05-14 Application filed by Amgen Inc filed Critical Amgen Inc

2007-05-15 Application granted granted Critical

2007-05-15 Publication of ATE361318T1 publication Critical patent/ATE361318T1/de

Links

230000004913 activation Effects 0.000 title 1
229920001184 polypeptide Polymers 0.000 title 1
102000004196 processed proteins & peptides Human genes 0.000 title 1
108090000765 processed proteins & peptides Proteins 0.000 title 1
101000795167 Homo sapiens Tumor necrosis factor receptor superfamily member 13B Proteins 0.000 abstract 7
102100029675 Tumor necrosis factor receptor superfamily member 13B Human genes 0.000 abstract 7
102000006942 B-Cell Maturation Antigen Human genes 0.000 abstract 6
108010008014 B-Cell Maturation Antigen Proteins 0.000 abstract 6
BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 abstract 5
210000001744 T-lymphocyte Anatomy 0.000 abstract 5
201000010099 disease Diseases 0.000 abstract 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
101150052424 AGP3 gene Proteins 0.000 abstract 3
101000678193 Mus musculus Alpha-1-acid glycoprotein 3 Proteins 0.000 abstract 3
ULDWTSQHEYEWRZ-CBEYZXOKSA-N ansamitocinoside p-3 Chemical compound C(/[C@H]([C@@]1(O)C[C@H](OC(=O)N1)[C@@H](C)[C@@H]1O[C@@]1(C)[C@@H](OC(=O)C(C)C)CC1=O)OC)=C\C=C(C)\CC(C=2)=CC(OC)=C(Cl)C=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O ULDWTSQHEYEWRZ-CBEYZXOKSA-N 0.000 abstract 3
239000003814 drug Substances 0.000 abstract 3
238000001727 in vivo Methods 0.000 abstract 3
230000001419 dependent effect Effects 0.000 abstract 2
230000028996 humoral immune response Effects 0.000 abstract 2
102000005962 receptors Human genes 0.000 abstract 2
108020003175 receptors Proteins 0.000 abstract 2
229940124597 therapeutic agent Drugs 0.000 abstract 2
208000023275 Autoimmune disease Diseases 0.000 abstract 1
101100537522 Homo sapiens TNFSF13B gene Proteins 0.000 abstract 1
206010025323 Lymphomas Diseases 0.000 abstract 1
206010028980 Neoplasm Diseases 0.000 abstract 1
206010052779 Transplant rejections Diseases 0.000 abstract 1
102100036922 Tumor necrosis factor ligand superfamily member 13B Human genes 0.000 abstract 1
201000011510 cancer Diseases 0.000 abstract 1
210000004027 cell Anatomy 0.000 abstract 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 abstract 1
235000018417 cysteine Nutrition 0.000 abstract 1
238000000338 in vitro Methods 0.000 abstract 1
230000003993 interaction Effects 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1
230000035755 proliferation Effects 0.000 abstract 1
230000000638 stimulation Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Rheumatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Cell Biology (AREA)
Toxicology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Transplantation (AREA)
Pain & Pain Management (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Dermatology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Saccharide Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

AT01935466T 2000-05-12 2001-05-14 Polypeptiden, die die april-vermittelte aktivierung von t-und b-zellen hemmen ATE361318T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US20403900P	2000-05-12	2000-05-12
US21459100P	2000-06-27	2000-06-27

Publications (1)

Publication Number	Publication Date
ATE361318T1 true ATE361318T1 (de)	2007-05-15

Family

ID=26899121

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT01935466T ATE361318T1 (de)	2000-05-12	2001-05-14	Polypeptiden, die die april-vermittelte aktivierung von t-und b-zellen hemmen

Country Status (10)

Country	Link
US (2)	US6774106B2 (de)
EP (1)	EP1280826B1 (de)
JP (1)	JP2003533218A (de)
AT (1)	ATE361318T1 (de)
AU (3)	AU2001263114A1 (de)
CA (1)	CA2408617A1 (de)
DE (1)	DE60128216T2 (de)
ES (1)	ES2287130T3 (de)
MX (1)	MXPA02011130A (de)
WO (2)	WO2001087977A2 (de)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6541224B2 (en)	1996-03-14	2003-04-01	Human Genome Sciences, Inc.	Tumor necrosis factor delta polypeptides
US7217788B2 (en)	1996-03-14	2007-05-15	Human Genome Sciences, Inc.	Human tumor necrosis factor delta polypeptides
US6812327B1 (en) *	1996-10-25	2004-11-02	Human Genome Sciences, Inc.	Neutrokine-alpha polypeptides
US8212004B2 (en) *	1999-03-02	2012-07-03	Human Genome Sciences, Inc.	Neutrokine-alpha fusion proteins
WO2001060397A1 (en) *	2000-02-16	2001-08-23	Genentech, Inc.	Uses of agonists and antagonists to modulate activity of tnf-related molecules
US7833529B1 (en)	1999-01-07	2010-11-16	Zymogenetics, Inc.	Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
CN100447244C (zh) *	1999-08-17	2008-12-31	比奥根艾迪克Ma公司	Baff受体(bcma),一种免疫调节剂
UA74798C2 (uk) *	1999-10-06	2006-02-15	Байоджен Айдек Ма Інк.	Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
US20040013674A1 (en) *	2001-04-27	2004-01-22	Christine Ambrose	Taci as an anti-tumor agent
US7371388B1 (en)	2000-05-04	2008-05-13	Human Genome Sciences, Inc.	Treatment of Sjogren's syndrome by administration of TR18 polypeptides
PT2281843T (pt) *	2000-06-16	2017-01-02	Human Genome Sciences Inc	Anticorpos que se ligam imunoespecificamente a blys
US7220840B2 (en)	2000-06-16	2007-05-22	Human Genome Sciences, Inc.	Antibodies that immunospecifically bind to B lymphocyte stimulator protein
US7879328B2 (en)	2000-06-16	2011-02-01	Human Genome Sciences, Inc.	Antibodies that immunospecifically bind to B lymphocyte stimulator
AU8506601A (en) *	2000-08-18	2002-03-04	Dyax Corp	Binding polypeptides for b lymphocyte stimulator protein (blys)
AU2001288301A1 (en)	2000-08-18	2002-03-04	Human Genome Sciences, Inc.	Binding polypeptides and methods based thereon
AU2002215753A1 (en) *	2000-12-07	2002-06-18	The University Of British Columbia	Caml-binding peptides
WO2002066516A2 (en) *	2001-02-20	2002-08-29	Zymogenetics, Inc.	Antibodies that bind both bcma and taci
EP1401870A4 (de)	2001-05-24	2006-04-19	Human Genome Sciences	Antikörper gegen tumor necrosis factor delta (april)
BRPI0209933B8 (pt) *	2001-05-24	2021-05-25	Zymogenetics Inc	proteína de fusão, e, molécula de ácido nucleico
BR0211614A (pt) *	2001-08-03	2006-10-31	Genentech Inc	polipeptìdeo tacis e br3 e empregos dos mesmos
CA2467521A1 (en) *	2001-11-16	2003-07-10	Human Genome Sciences, Inc.	Antibodies that immunospecifically bind to blys
WO2004011611A2 (en) *	2002-07-25	2004-02-05	Genentech, Inc.	Taci antibodies and uses thereof
EP1558278B1 (de) *	2002-10-11	2009-09-02	ZymoGenetics, Inc.	Herstellung von homotrimeren fusionsproteinen
WO2004060911A2 (en)	2002-12-30	2004-07-22	Amgen Inc.	Combination therapy with co-stimulatory factors
US20050163775A1 (en) *	2003-06-05	2005-07-28	Genentech, Inc.	Combination therapy for B cell disorders
JP2007526220A (ja)	2003-06-05	2007-09-13	ジェネンテック・インコーポレーテッド	Ｂ細胞疾患の併用療法
WO2005003771A1 (en) *	2003-07-02	2005-01-13	Science & Technology Corporation @ Unm	Two-layer antibody capture system
US20070249530A1 (en)	2004-01-29	2007-10-25	Genentech, Inc.	Bcma Polypeptides and Uses Thereof
AU2005305182A1 (en) *	2004-11-04	2006-05-18	Genentech, Inc.	Polypeptides that bind BAFF and/or APRIL
US7947805B2 (en)	2004-12-23	2011-05-24	Merck Serono S.A.	BCMA polypeptides and uses thereof
WO2007019573A2 (en)	2005-08-09	2007-02-15	Zymogenetics, Inc.	Methods for the treatment and prevention of abnormal cell proliferation using taci-fusion molecules
EP1922080A2 (de)	2005-08-09	2008-05-21	ZymoGenetics, Inc.	Verfahren zur behandlung von b-zell-malignomen mittels taci-ig-fusionsmolekül
WO2007142667A2 (en)	2005-10-13	2007-12-13	Human Genome Sciences, Inc.	Treatment of patients with autoantibody positive disease
US9168286B2 (en)	2005-10-13	2015-10-27	Human Genome Sciences, Inc.	Methods and compositions for use in treatment of patients with autoantibody positive disease
ES2618543T3 (es)	2005-11-23	2017-06-21	Genentech, Inc.	Métodos y composiciones relacionados con ensayos de linfocitos B
WO2007123765A2 (en)	2006-03-31	2007-11-01	Human Genome Sciences Inc.	Neutrokine-alpha and neutrokine-alpha splice variant
BRPI0711823A2 (pt)	2006-05-15	2012-01-17	Ares Trading Sa	métodos para tratamento de doenças auto-imunes com uma molécula de fusão taci-ig
WO2008025747A1 (en) *	2006-08-28	2008-03-06	Ares Trading S.A.	Process for the purification of fc-fusion proteins
SI2061803T2 (sl) *	2006-08-28	2023-01-31	Ares Trading S.A.	Postopek za čiščenje proteinov, ki vsebujejo FC
PE20081140A1 (es) *	2006-10-25	2008-09-22	Amgen Inc	Agentes terapeuticos a base de peptidos derivados de toxinas
HUE030134T2 (en)	2007-10-16	2017-04-28	Zymogenetics Inc	Combination of transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) and anti-CD20 agents for the treatment of autoimmune diseases
DK2219675T3 (da) *	2007-11-12	2013-12-02	Ares Trading Sa	Formuleringer for taci-immunglobulin-fusionsproteiner
CA2720682A1 (en) *	2008-04-25	2009-10-29	Zymogenetics, Inc.	Levels of bcma protein expression on b cells and use in diagnostic methods
WO2010075249A2 (en)	2008-12-22	2010-07-01	Genentech, Inc.	A method for treating rheumatoid arthritis with b-cell antagonists
WO2010093993A2 (en) *	2009-02-12	2010-08-19	Human Genome Sciences, Inc.	Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance
CA2754127C (en) *	2009-03-02	2017-04-18	Stichting Top Institute Pharma	Antibodies against a proliferating inducing ligand (april)
JP5996429B2 (ja)	2009-09-03	2016-09-21	ジェネンテック，インコーポレイテッド	関節リウマチの治療、診断及びモニターするための方法
WO2011109280A1 (en)	2010-03-05	2011-09-09	Lerner Research Institute	Methods and compositions to treat immune-mediated disorders
WO2012032112A1 (en) *	2010-09-10	2012-03-15	Cellerix, S.A.	Stem cell culture media and methods
EP3974453A3 (de) *	2010-11-16	2022-08-03	Amgen Inc.	Mittel und verfahren zur behandlung von mit bcma-expression korrelierenden erkrankungen
MX353143B (es)	2011-02-28	2017-12-20	Genentech Inc	Marcadores biologicos y metodos para pronosticar respuesta a antagonistas de celulas b.
TWI679212B (zh)	2011-11-15	2019-12-11	美商安進股份有限公司	針對ｂｃｍａ之e3以及ｃｄ３的結合分子
AR095374A1 (es)	2013-03-15	2015-10-14	Amgen Res Munich Gmbh	Moléculas de unión para bcma y cd3
NL2011406C2 (en) *	2013-09-06	2015-03-10	Bionovion Holding B V	Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides.
BR112016018100A2 (pt)	2014-02-07	2018-02-20	Univ Mcmaster	acoplador antigênico de células t trifuncional, métodos e usos do mesmo
WO2016003876A1 (en)	2014-07-03	2016-01-07	Oklahoma Medical Research Foundation	Treatment of multiple sclerosis and neuromyelitis optica
NL2014108B1 (en)	2015-01-09	2016-09-30	Aduro Biotech Holdings Europe B V	Altered april binding antibodies.
US9708412B2 (en)	2015-05-21	2017-07-18	Harpoon Therapeutics, Inc.	Trispecific binding proteins and methods of use
FI3380522T3 (fi)	2015-11-25	2024-01-16	Visterra Inc	Vasta-ainemolekyylejä april-proteiinille ja niiden käyttöjä
EP3493844A4 (de)	2016-05-20	2021-03-24	Harpoon Therapeutics Inc.	Einzeldomänen-serumalbuminbindendes protein
KR20250175345A (ko)	2016-06-21	2025-12-16	테네오바이오, 인코포레이티드	Cd3 결합 항체
PE20241349A1 (es)	2016-09-14	2024-07-03	Teneobio Inc	Anticuerpos de union a cd3
IL317134A (en)	2016-12-21	2025-01-01	Teneobio Inc	An antibody containing only heavy chains that binds a human B-cell maturation antigen, a pharmaceutical composition containing the same, its use in the treatment of B-cell disorders and a method for its preparation
KR20250007003A (ko)	2017-06-20	2025-01-13	테네오바이오, 인코포레이티드	항-bcma 중쇄-단독 항체
CA3064632A1 (en)	2017-06-20	2018-12-27	Dana-Farber Cancer Institute, Inc.	Methods for modulating regulatory t cells, regulatory b cells, and immune responses using modulators of the april-taci interaction
JP7385556B2 (ja) *	2017-09-01	2023-11-22	デイナファーバーキャンサーインスティチュート，インコーポレイテッド	Ｂｃｍａ抗原に特異的な免疫原性ペプチドおよびその使用
JP7749319B2 (ja)	2017-10-10	2025-10-06	アルパインイミューンサイエンシズインコーポレイテッド	Ｃｔｌａ－４変異型免疫調節タンパク質およびそれらの使用
CN111479925B (zh)	2017-10-12	2024-03-08	麦克马斯特大学	具有y182t突变的t细胞-抗原偶联物及其方法和用途
MX2020003915A (es)	2017-10-13	2020-10-08	Harpoon Therapeutics Inc	Proteinas trispecificas y metodos de uso.
IL315737A (en)	2017-10-13	2024-11-01	Harpoon Therapeutics Inc	B-cell maturation antigen-binding proteins
KR102870868B1 (ko)	2018-06-01	2025-10-15	노파르티스 아게	Bcma에 대한 결합 분자 및 이의 용도
US11110123B2 (en)	2018-07-17	2021-09-07	Triumvira Immunologics Usa, Inc.	T cell-antigen coupler with various construct optimizations
US12195544B2 (en)	2018-09-21	2025-01-14	Harpoon Therapeutics, Inc.	EGFR binding proteins and methods of use
US10815311B2 (en)	2018-09-25	2020-10-27	Harpoon Therapeutics, Inc.	DLL3 binding proteins and methods of use
WO2020206330A1 (en)	2019-04-05	2020-10-08	Teneobio, Inc.	Heavy chain antibodies binding to psma
JP7489407B2 (ja)	2019-05-21	2024-05-23	ノバルティスアーゲー	Ｃｄ１９結合分子及びその使用
CR20210622A (es)	2019-06-14	2022-06-27	Teneobio Inc	Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3
WO2021121250A1 (zh) *	2019-12-17	2021-06-24	深圳市菲鹏生物治疗股份有限公司	Bcma结合抗体及其用途
IL297601A (en)	2020-04-29	2022-12-01	Teneobio Inc	Multispecific heavy chain antibodies with modified heavy chain constant regions
EP4146684A2 (de)	2020-05-08	2023-03-15	Alpine Immune Sciences, Inc.	April- und baff-hemmende immunmodulatorische proteine mit und ohne t-zell-hemmendes protein und verfahren zur verwendung davon
AU2022283819A1 (en)	2021-06-01	2024-01-04	Triumvira Immunologics Usa, Inc.	Claudin 18.2 t cell-antigen couplers and uses thereof
US11453723B1 (en)	2021-06-25	2022-09-27	Mcmaster University	BCMA T cell-antigen couplers and uses thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4289872A (en)	1979-04-06	1981-09-15	Allied Corporation	Macromolecular highly branched homogeneous compound based on lysine units
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4699880A (en)	1984-09-25	1987-10-13	Immunomedics, Inc.	Method of producing monoclonal anti-idiotype antibody
US5229490A (en) *	1987-05-06	1993-07-20	The Rockefeller University	Multiple antigen peptide system
WO1993021259A1 (en)	1992-04-14	1993-10-28	Cornell Research Foundation Inc.	Dendritic based macromolecules and method of production
US6096871A (en)	1995-04-14	2000-08-01	Genentech, Inc.	Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
JP4046354B2 (ja)	1996-03-18	2008-02-13	ボードオブリージェンツ，ザユニバーシティオブテキサスシステム	増大した半減期を有する免疫グロブリン様ドメイン
PT939804E (pt)	1996-10-25	2005-11-30	Human Genome Sciences Inc	Neutroquina alfa
WO1998027114A2 (en)	1996-12-17	1998-06-25	Schering Corporation	Mammalian cell surface antigens; related reagents
US5969102A (en)	1997-03-03	1999-10-19	St. Jude Children's Research Hospital	Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof
CA2232743A1 (en)	1997-04-02	1998-10-02	Smithkline Beecham Corporation	A tnf homologue, tl5
JP2002504818A (ja)	1997-06-06	2002-02-12	リジェネロンファーマシューティカルズ，インコーポレイテッド	リガンドファミリーのｎｔｎ−２メンバー
AU7608898A (en)	1997-06-06	1998-12-21	Regeneron Pharmaceuticals, Inc.	Ntn-2 member of tnf ligand family
US6171787B1 (en)	1997-06-26	2001-01-09	Abbott Laboratories	Member of the TNF family useful for treatment and diagnosis of disease
WO1999011791A2 (en)	1997-09-05	1999-03-11	University Of Washington	Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents
CZ294615B6 (cs)	1997-09-12	2005-02-16	Apotech R & D Sa	Léčivo obsahující protilátky reaktivní s polypeptidovým ligandem APRIL pro léčení rakoviny
EP1012270A2 (de)	1997-09-12	2000-06-28	Apotech R&D S.A.	Kay: ein neues immunsystem-protein
US6297022B1 (en)	1997-10-08	2001-10-02	Smithkline Beecham Corporation	Method of identifying agonists and antagonists for tumor necrosis related receptor TR1
WO1999026976A1 (en)	1997-11-26	1999-06-03	Eli Lilly And Company	Tnf ligand family gene
NZ527900A (en)	1997-12-03	2005-02-25	Genentech Inc	PRO361 polypeptides and nucleic acids with homology to mucin and chitinase
AU2093499A (en)	1997-12-30	1999-07-19	Chiron Corporation	Members of tnf and tnfr families
AU2212299A (en)	1998-01-05	1999-07-26	Genentech Inc.	Compositions and methods for the treatment of tumor
WO2001060397A1 (en)	2000-02-16	2001-08-23	Genentech, Inc.	Uses of agonists and antagonists to modulate activity of tnf-related molecules
US6660843B1 (en) *	1998-10-23	2003-12-09	Amgen Inc.	Modified peptides as therapeutic agents
SI1642972T1 (sl) *	1999-01-07	2010-05-31	Zymogenetics Inc	Terapevtske uporabe BR X topnih receptorjev
AU4986700A (en) *	1999-05-06	2000-11-21	National Jewish Medical And Research Center	Tall-1 nucleic acid molecules, proteins, receptors and methods of use thereof
CN100447244C (zh) *	1999-08-17	2008-12-31	比奥根艾迪克Ma公司	Baff受体(bcma),一种免疫调节剂
UA74798C2 (uk) *	1999-10-06	2006-02-15	Байоджен Айдек Ма Інк.	Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами

2001
- 2001-05-14 WO PCT/US2001/015504 patent/WO2001087977A2/en not_active Ceased
- 2001-05-14 US US09/854,864 patent/US6774106B2/en not_active Expired - Fee Related
- 2001-05-14 AU AU2001263114A patent/AU2001263114A1/en not_active Abandoned
- 2001-05-14 AT AT01935466T patent/ATE361318T1/de not_active IP Right Cessation
- 2001-05-14 EP EP01935466A patent/EP1280826B1/de not_active Expired - Lifetime
- 2001-05-14 ES ES01935466T patent/ES2287130T3/es not_active Expired - Lifetime
- 2001-05-14 MX MXPA02011130A patent/MXPA02011130A/es active IP Right Grant
- 2001-05-14 US US09/855,158 patent/US20020086018A1/en not_active Abandoned
- 2001-05-14 DE DE60128216T patent/DE60128216T2/de not_active Expired - Fee Related
- 2001-05-14 CA CA002408617A patent/CA2408617A1/en not_active Abandoned
- 2001-05-14 WO PCT/US2001/015567 patent/WO2001087979A2/en not_active Ceased
- 2001-05-14 AU AU2001261557A patent/AU2001261557B2/en not_active Ceased
- 2001-05-14 JP JP2001585195A patent/JP2003533218A/ja not_active Withdrawn
- 2001-05-14 AU AU6155701A patent/AU6155701A/xx active Pending

Also Published As

Publication number	Publication date
DE60128216T2 (de)	2008-01-10
DE60128216D1 (de)	2007-06-14
WO2001087979A2 (en)	2001-11-22
ES2287130T3 (es)	2007-12-16
AU2001261557B2 (en)	2005-06-30
AU6155701A (en)	2001-11-26
AU2001263114A1 (en)	2001-11-26
WO2001087977A2 (en)	2001-11-22
CA2408617A1 (en)	2001-11-22
WO2001087979A3 (en)	2002-05-30
WO2001087977A3 (en)	2002-06-20
EP1280826A2 (de)	2003-02-05
JP2003533218A (ja)	2003-11-11
MXPA02011130A (es)	2003-03-10
US20020081296A1 (en)	2002-06-27
EP1280826B1 (de)	2007-05-02
US6774106B2 (en)	2004-08-10
US20020086018A1 (en)	2002-07-04

Legal Events

Date	Code	Title	Description
2007-11-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE361318T1 (de)	2007-05-15	Polypeptiden, die die april-vermittelte aktivierung von t-und b-zellen hemmen
ATE399553T1 (de)	2008-07-15	Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
ATE293989T1 (de)	2005-05-15	Verwendung von eph-rezeptor-antagonisten und agonisten zur behandlung von vaskulären krankheiten
EP2447280A3 (de)	2012-06-20	VEGF Analoga und Verfahren zur Verwendung davon
TR200000913T2 (tr)	2001-01-22	Tıbbi maddeler
DK1742644T3 (da)	2012-04-16	Terapeutisk sammensætning indeholdende mindst et pyrrolbenzodiazepin-derivat og fludarabin
CO5611160A2 (es)	2006-02-28	Conjugados de agentes terapeuticos o citotoxicos y peptidos biologicamente activos
FR14C0051I2 (fr)	2019-01-18	Dialkylfumarates pour le traitement de maladies autoimmunes
NZ707292A (en)	2017-06-30	Activin-actrii antagonists and uses for increasing red blood cell levels
DE69830404D1 (de)	2005-07-07	P38-inhibitoren
CY1116107T1 (el)	2017-02-08	Ενωσεις για χρηση στην αγωγη αυτοανοσων παθησεων, ανοσο-αλλεργικων παθησεων και απορριψης μεταμοσχευσης οργανων ή ιστων
DK0839026T3 (da)	2002-01-21	Micellære polyether-blokcopolymerkompositioner til målretning af biologiske midler
ATE494899T1 (de)	2011-01-15	Zusammensetzung bestehend aus phy906 und chemotherapeutika
NO971341L (no)	1997-05-14	Promoter for reseptor tyrosinkinase TIE
DE602004017326D1 (de)	2008-12-04	Tetrahydrocarbazolderivate und deren pharmazeutische verwendung
ATE543491T1 (de)	2012-02-15	Kombinationspräparat enthaltend ibuprofen und paracetamol
ATE286074T1 (de)	2005-01-15	Gegen ccr5 gerichtete antikörperkonstrukte und ihre verwendung in der behandlung von autoimmunkrankheiten
EA200601288A1 (ru)	2006-12-29	Производные 1,3-дифенилпроп-2-ен-1-она, способ их получения и применение
BR0305018A (pt)	2004-09-21	Células dendrìticas tolerogênicas e usos terapêuticos para as mesmas
MXPA02005069A (es)	2003-09-25	Agentes de enlace especificos para t3 y metodos para su uso.
DE60319135D1 (de)	2008-03-27	Peptide, die die heparinbindungsdomäne von vegf und vegfr-2 binden
EP1611151A4 (de)	2007-08-22	Stq-peptide
IL171384A (en)	2010-12-30	Use of slurp-1 in the preparation of medicaments for the treatment of neurological disorders
EA200000909A1 (ru)	2001-06-25	ФОРМА VI 5,6-ДИХЛОР-2-(ИЗОПРОПИЛАМИНО)-1-(b-L-РИБОФУРАНОЗИЛ)-1H-БЕНЗИМИДАЗОЛА
TNSN05315A1 (en)	2007-07-10	Method of inhibiting receptor tyrosine kinases with an extracellular antagonist and an intracellular antagonist